Screener
Axsome Therapeutics AXSM Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Royalty revenue and milestone revenue | 1,803 | 1,105 |
| Total revenues | 191,203 | 121,463 |
| Operating expenses: | ||
| Cost of revenue (excluding amortization and depreciation) | 14,725 | 9,789 |
| Research and development | 52,677 | 44,785 |
| Selling, general and administrative | 184,996 | 120,787 |
| Loss in fair value of contingent consideration | 590 | 1,512 |
| Intangible asset amortization | 1,572 | 1,572 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's total cost of revenue?
- Axsome Therapeutics (AXSM) reported total cost of revenue of $14.73M in Q1 2026.
- How has Axsome Therapeutics's total cost of revenue changed year-over-year?
- Axsome Therapeutics's total cost of revenue increased by 50.4% year-over-year, from $9.79M to $14.73M.
- What is the long-term trend for Axsome Therapeutics's total cost of revenue?
- Over 3 years (2022 to 2025), Axsome Therapeutics's total cost of revenue has grown at a 109.0% compound annual growth rate (CAGR), from $5.2M to $47.48M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Axsome Therapeutics's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude